Brydon L Bennett

USPTO Granted Patents = 15 (Patent Applications = 2)

CIPO Patents = 1 (Patent Applications = 3)

EPO Patents = 3 (Patent Applications = 4)

Average Co-Inventor Count = 8.5

ph-index = 8

Forward Citations = 145(Granted Patents)

Company Filing History:

11 out of 169

Signal Pharmaceuticals, Inc.

where one patent can have more than one assignee

Years Active: 2006-2024

Loading Chart...

15 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12129237 - Substituted diaminocarboxamide and diaminocarbonitrile pyrimidines, compositions thereof, and methods of treatment therewith (2024-10-29),

2. 11028093 - 4,6-substituted-pyrazolo[1,5-a]pyrazines as janus kinase inhibitors (2021-06-08),

3. 10730880 - 4,6-substituted-pyrazolo[1,5-a]pyrazines as Janus kinase inhibitors (2020-08-04),

4. 10428145 - PD-1 binding proteins and methods of use thereof (2019-10-01),

5. 10266500 - Substituted diaminocarboxamide and diaminocarbonitrile pyrimidines, compositions thereof, and methods of treatment therewith (2019-04-23),

6. 10189845 - 4,6-substituted-pyrazolo[1,5-a]pyrazines as janus kinase inhibitors (2019-01-29),

7. 9783505 - Substituted diaminopyrimidyl compounds, compositions thereof, and methods of treatment therewith (2017-10-10),

8. 9701643 - Substituted diaminocarboxamide and diaminocarbonitrile pyrimidines, compositions thereof, and methods of treatment therewith (2017-07-11),

9. 9556126 - Substituted diaminopyrimidyl compounds, compositions thereof, and methods of treatment therewith (2017-01-31),

10. 9139534 - Substituted diaminocarboxamide and diaminocarbonitrile pyrimidines, compositions thereof, and methods of treatment therewith (2015-09-22),

11. 8680076 - Methods of treatment, improvement and prevention using haloaryl substituted aminopurines (2014-03-25),

12. 8440661 - Methods of modulating inflammatory cell recruitment and gene expression using haloaryl substituted aminopurines (2013-05-14),

13. 7759342 - Methods of treatment and prevention using haloaryl substituted aminopurines (2010-07-20),

14. 7335676 - Methods for treating inflammatory conditions or inhibiting JNK (2008-02-26),

15. 7119114 - Pyrazoloanthrone and derivatives thereof as JNK inhibitors and compositions and methods related thereto (2006-10-10),

Title: Innovations of Brydon L Bennett: A Pioneer in Pharmacological Patents

Introduction

Brydon L Bennett, an esteemed inventor based in San Diego, CA, has made significant contributions to the field of pharmacology, exemplified by his impressive portfolio of 15 patents. His innovations focus primarily on developing compounds that offer therapeutic benefits for a variety of diseases, particularly those related to JAK kinases.

Latest Patents

Among his notable recent patents are the advancements in substituted diaminocarboxamide and diaminocarbonitrile pyrimidines. These compounds are specifically designed as inhibitors of JAK kinases, which play essential roles in autoimmune diseases, inflammatory conditions, and hematologic disorders. His comprehensive patent describes the Diaminopyrimidine Compounds with intricate structures that target janus kinase activities, aiming to mitigate challenges associated with transplanted organ rejection and related diseases.

Career Highlights

Bennett's career has seen him thrive in prestigious roles at companies such as Signal Pharmaceuticals, Inc. and Celgene Corporation. His work in these organizations enabled him to develop his innovative ideas into actual products that address complex medical issues, showcasing his role as a significant contributor to pharmaceutical innovation.

Collaborations

Throughout his career, Brydon L Bennett has collaborated with notable colleagues, including Yoshitaka Satoh and Stephen Norris. These partnerships have fostered an environment of shared ideas and expertise, enhancing the quality and impact of his inventions.

Conclusion

In conclusion, Brydon L Bennett stands out as a prominent inventor, pushing the boundaries of pharmacological research and development. His continued efforts to innovate in the realm of JAK kinase inhibitors not only highlight his dedication but also illustrate the potential for his inventions to transform treatment methodologies for various diseases.

This text is generated by artificial intelligence and may not be accurate.